Sage Therapeutics (NASDAQ:SAGE) Price Target Cut to $25.00 by Analysts at HC Wainwright
by The Cerbat Gem
The Cerbat Gem— Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its price objective reduced by stock analysts at HC Wainwright from $28.00 to $25.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside […]
The Cerbat Gem—Onsemi (NASDAQ:ON) Price Target Cut to $85.00 by Analysts at Deutsche Bank Aktiengesellschaft. Onsemi (NASDAQ:ON – Free Report) had its price target lowered by Deutsche Bank Aktiengesellschaft from $90.00 to $85.00 in a research note issued to investors on Tuesday, Benzinga reports. Deutsche Bank Aktiengesellschaft currently has a buy rating on the semiconductor company’s stock. A number of other brokerages have also issued reports on ON. Rosenblatt Securities […]
The Cerbat Gem—Evercore ISI Cuts Hub Group (NASDAQ:HUBG) Price Target to $44.00. Hub Group (NASDAQ:HUBG – Get Free Report) had its target price decreased by research analysts at Evercore ISI from $46.00 to $44.00 in a research note issued on Friday, Benzinga reports. The firm currently has an “outperform” rating on the transportation company’s stock. Evercore ISI’s price target indicates a potential upside of 9.29% from the […]
The Cerbat Gem—Blueprint Medicines (NASDAQ:BPMC) Price Target Increased to $125.00 by Analysts at JMP Securities. Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective raised by JMP Securities from $114.00 to $125.00 in a report issued on Friday, Benzinga reports. The firm currently has a “market outperform” rating on the biotechnology company’s stock. JMP Securities’ target price suggests a potential upside of 16.62% from the company’s previous close. […]